Chinese Journal of Pharmaceutics May 2008 p.124
, Tel.13998206747, E mail yang_rui1983@163.com;
, Tel. 024 23986360, E mail xiaohu6408_cn@sina.com (film hydration method) (reverse phase evaporation method) (dehydration-rehydration method) (proniosome method) (ether injection method) (ethanol injection method) (hand shaking method) (remote loading method) Table 1 Advantages and disadvantages of different methods of determination of entrapment efficiency
Large volumes of dialysate required(may not be
suitable for drugs requiring specialised disposal)
May lead to the destruction of fragile systems
Not suitable for highly viscous formulations
Not suitable for formulations with a large particle
Not suitable for highly viscous formulations
Not suitable for formulations with a large particle
Not suitable for formulations with a large particle
[1] BEHROOZ N. Effect of cholesterol and temperature on the elastic properties of niosomal membranes [J]. International
Journal of Pharmaceutics, 2005, 300: 95 101.
[2] HANDJANIVILA R M, RLBIER A, RONDOT B, et al. Dispersion of lamellar phases of non-ionic lipids in cosmetic
products [J]. International journal of cosmetic Science, 1979, 1: 303 314.
ISRAELACHVILI J N. Intermolecular and Surface Forces [M]. Sydney: Academic Press, 1985: 121.
[5] UCHEGBU I F, VYAS S P. Non-ionic surfactant based vesicles (niosomes) in drug delivery [J]. International Journal
[6] PILLAI G K, SALIM M L D. Enhanced inhibition of platelet aggregation in-vitro by niosome-encapsulated
indomethacin [J]. International Journal of Pharmaceutics, 1999, 193:123 127.
[7] DEVARAJ G N, PARAKH S R, DEVRAJ R, et al. Release studies on niosomes containing fatty alcohols as bilayer
stabilizers instead of cholesterol [J]. Journal of Colloid and Interface Science, 2002, 251: 360 365.
[8] ARUNOTHAYANUN P, UCHEGBU I F, CRAIG D Q M, et al. In vitro/in vivo characterisation of polyhedral
niosomes [J]. International Journal of Pharmaceutics, 1999, 183: 57 61.
[9] VYAS S P, VENKATESAN N. Poly(phthaloyl-L-lysine)-coated multilamellar vesicles for controlled drug delivery: in vitro and in vivo performance evaluation [J]. Pharmaceutica Acta Helvetiae, 1999, 74: 51 58.
[10] GOPINATH D, RAVI D, RAO B R, et al. Ascorbyl palmitate vesicles (aspasomes): Formation, characterization and
applications [J]. International Journal of Pharmaceutics, 2004, 271: 95 113.
[11] GIRIGOSWAMI A, DAS S, DE S. Fluorescence and dynamic light scattering studies of niosomes-membrane mimetic
systems [J]. Spectrochimica Acta Part A, 2006, 64: 859 866.
[12] PARDAKHTY A, VARSHOSAZ J, ROUHOLAMINI A. In vitro study of polyoxyethylene alkyl ether niosomes for
delivery of insulin [J]. International Journal of Pharmaceutics, 2007, 328: 130 141.
[13] JAIN S, SINGH P, MISHRA V, et al. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization
against Hepatitis B [J]. Immunology Letters, 2005, 101: 41 49.
[14] AGGARWAL D, PAL D, MITRA A K, et al. Study of the extent of ocular absorption of acetazolamide from a
developed niosomal formulation, by microdialysis sampling of aqueous humor [J]. International Journal of
[15] UCHEGBU I F, DUNCAN R. Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin
(PK1): Effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of
body distribution [J]. International Journal of Pharmaceutics, 1997, 155: 7 17.
[16] PERRIEA Y, BARRALET J E, MCNEIL S, et al. Surfactant vesicle-mediated delivery of DNA vaccines via the
subcutaneous route [J]. International Journal of Pharmaceutics, 2004, 284: 31 41.
[17] VORA B, KHOPADE A J, JAIN N K. Proniosome based transdermal delivery of levonorgestrel for effective
contraception [J]. Journal of Controlled Release, 1998, 54: 149 165.
[18] ALSARRA I A, BOSELA A A, AHMED S M, et al. Proniosomes as a drug carrier for transdermal delivery of
ketorolac [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59: 485 490.
[19] FANG J Y, HONG C T, CHIU W T, et al. Effect of liposomes and niosomes on skin permeation of enoxacin [J].
International Journal of Pharmaceutics, 2001, 219: 61 72.
[20] DUFES C, SCHATZLEIN A G, TETLEY L, et al. Niosomes and polymeric chitosan based vesicles bearing transferrin
and glucose ligands for drug targeting [J]. Pharmaceutical Research, 2000, 17(10): 1250 1258.
[21] UCHEGBU I F. The biodistribution of novel 200-nm palmitoyl muramic acid vesicles [J]. International Journal of
[22] HOFLAND H E J, BOUWSTR A, et al. Safety aspects of non-ionic surfactant vesicles-a toxicity study related to the
physicochemical characteristics of non-ionic surfactants [J]. Journal of Pharmacy and Pharmacology, 1992, 44:
[23] DIMITRIJEVIC D, LAMANDIN C, UCHEGBU I F, et al. The effect of monomers and of micellar and vesicular forms
of non-ionic surfactants (Solulan C24 and Solulan 16) on Caco-2 cell monolayers [J]. Journal of Pharmacy and
[24] DUFES C, MULLER J M, COUET W, et al. Anticancer drug delivery with transferrin targeted polymeric chitosan
vesicles [J]. Pharmaceutical Research, 2004, 21(1): 101 107.
[25] AGARWAL R, KATARE O P, VYAS S P. Preparation and in vitro evaluation of liposomal/niosomal delivery systems
for antipsoriatic drug dithranol [J]. International Journal of Pharmaceutics, 2001, 228: 43 52.
[26] MANCONI M, SINICO C, VALENTI D, et al. Niosomes as carriers for tretinoin I Preparation and properties [J].
International Journal of Pharmaceutics, 2002, 234: 237 248.
[27] ERDOGAN S, YEKTAOZER A, BILGILI H. In vivo behaviour of vesicular urokinase [J]. International Journal of
[28] PALOZZA P, MUZZALUPO R, TROMBINO S, et al. Solubilization and stabilization of β-carotene in
niosomes:Delivery to cultured cells [J]. Chemistry and Physics of Lipids, 2006, 139: 32 42.
[29] UCHEGBU I F, MCCARTHY D, SCHATZLEIN, et al. Phase-transitions in aqueous dispersions of the hexadecyl
diglycerol ether C16G2 non-ionic surfactant, cholesterol and cholesteryl poly-24-oxyethylene ether-vesicles, tubules,
discomes and micelles [J]. Stp Pharma Sciences, 1996, 6: 33 43.
[30] GIANASI E, COCIANCICH F, UCHEGBU I F, et al. Pharmaceutical and biological characterization of a
doxorubicin-polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes [J]. International Journal
[31] WANG T, DENG Y J, GENG Y H, et al. Preparation of submicron unilamellar liposomes by freeze-drying double
emulsions [J]. Biochimica et Biophysica Acta , 2006, 1758: 222 231.
Progress of study on niosomes
(School of Pharmacy , Shenyang Pharmaceutical University , Shenyang 110016, China)
Abstract: Objective To introduce the research progress of niosomes. Methods Based on the recent
references, the concept, formation condition, composition, preparation, determination of entrapment
efficiency and toxicity study was reviewed, with focus on the preparation methods. Results and conclusions Niosome is a novel targeted drug delivery system, with a wide and promising future. Key words: pharmaceutics; niosomes; Israelachvili theory; preparation; entrapment efficiency; toxicity
The H1N1 Vaccine Coding Guidelines have been updated to include the 90470 code recently released from the American Medical Association (AMA) for H1N1 vaccine administration. This new code or the previously communicated G9141 code can be used when billing the H1N1 vaccine administration for a CIGNA medical plan. CIGNA will reimburse health care professionals and facilities for the administration
The to facilitate your studying, the following list contains many of the terms and items found on the upcoming exam. Tetracycline, acne, papules, peeling lotion, topical antibiotic agent, comedones on her face. You tell her to apply retinoicacid, Retin A cream, dry skin, toenails, dermatitis, steroid creams, Psoriasis, Trichophyton rubrum infection, Atopic dermatitis,seborreheic dermatitis,